C21orf99 siRNA (h): sc-91410



The Power to Question

BACKGROUND

C21orf99 (ANKRD30BP2), also known as ankyrin repeat domain 30B pseudogene 2, CT85, CTSP1 or CTSP-1, is a 68 amino acid protein that, characteristic of CT (cancer/testis) antigens, displays a restricted expression pattern in normal tissues. Encoded by a gene that maps to human chromosome 21q11.2, C21orf99 is highly conserved and shares similarity to the 5' region of the breast differentiation antigen ANKRD30A gene. C21orf99 is predominantly expressed in testis and is also expressed in prostate, brain, placenta and trachea. C21orf99 is not expressed in lung, small intestine, breast, heart, uterus, bone marrow, fetal brain, colon, fetal liver, liver, thymus, salivary glands, spinal chord, kidney, spleen, muscle and adrenal gland. C21orf99 is suggested to produce humoral response in cancer patients due to its high expression in tumor cells.

REFERENCES

- Reymond, A., Friedli, M., Henrichsen, C.N., Chapot, F., Deutsch, S., Ucla, C., Rossier, C., Lyle, R., Guipponi, M. and Antonarakis, S.E. 2001. From PREDs and open reading frames to cDNA isolation: revisiting the human chromosome 21 transcription map. Genomics 78: 46-54.
- Parmigiani, R.B., Bettoni, F., Vibranovski, M.D., Lopes, M.H., Martins, W.K., Cunha, I.W., Soares, F.A., Simpson, A.J., de Souza, S.J. and Camargo, A.A. 2006. Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc. Natl. Acad. Sci. USA 103: 18066-18071.
- 3. Kim, H.N., Choi, D.W., Lee, K.T., Lee, J.K., Heo, J.S., Choi, S.H., Paik, S.W., Rhee, J.C. and Lowe, A.W. 2007. Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer. Pancreas 34: 325-334.
- 4. Rudchenko, S., Scanlan, M., Kalantarov, G., Yavelsky, V., Levy, C., Estabrook, A., Old, L., Chan, G.L., Lobel, L. and Trakht, I. 2008. A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen. BMC Cancer 8: 248.
- Parmigiani, R.B., Bettoni, F., Grosso, D.M., Lopes, A., Cunha, I.W., Soares, F.A., Carvalho, A.L., Fonseca, F. and Camargo, A.A. 2008. Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int. J. Cancer 122: 2385-2390.
- 6. Caballero, O.L. and Chen, Y.T. 2009. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100: 2014-2021.
- 7. Sarge, K.D., Xing, H. and Park-Sarge, O.K. 2009. Chromosome-wide analysis of protein binding and modifications. Methods Mol. Biol. 590: 223-233.
- 8. Ghafouri-Fard, S., Ousati Ashtiani, Z., Sabah Golian, B., Hasheminasab, S.M. and Modarressi, M.H. 2010. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch. Med. Res. 41: 195-200.
- Ghafouri-Fard, S., Abbasi, A., Moslehi, H., Faramarzi, N., Taba Taba Vakili, S., Mobasheri, M.B. and Modarressi, M.H. 2010. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br. J. Dermatol. 162: 772-779.

CHROMOSOMAL LOCATION

Genetic locus: ANKRD30BP2 (human) mapping to 21q11.2.

PRODUCT

C21orf99 siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see C21orf99 shRNA Plasmid (h): sc-91410-SH and C21orf99 shRNA (h) Lentiviral Particles: sc-91410-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

C21orf99 siRNA (h) is recommended for the inhibition of C21orf99 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor C21orf99 gene expression knockdown using RT-PCR Primer: C21orf99 (h)-PR: sc-91410-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com